TW200415994A - Food and medicine containing royal jelly - Google Patents
Food and medicine containing royal jelly Download PDFInfo
- Publication number
- TW200415994A TW200415994A TW092104299A TW92104299A TW200415994A TW 200415994 A TW200415994 A TW 200415994A TW 092104299 A TW092104299 A TW 092104299A TW 92104299 A TW92104299 A TW 92104299A TW 200415994 A TW200415994 A TW 200415994A
- Authority
- TW
- Taiwan
- Prior art keywords
- royal jelly
- blood pressure
- weeks
- food
- raw
- Prior art date
Links
- 229940109850 royal jelly Drugs 0.000 title claims abstract description 79
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 235000013305 food Nutrition 0.000 title claims abstract description 25
- 231100000957 no side effect Toxicity 0.000 claims abstract description 4
- 230000036772 blood pressure Effects 0.000 claims description 14
- 239000002075 main ingredient Substances 0.000 claims description 6
- 230000004531 blood pressure lowering effect Effects 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 abstract description 30
- 230000037406 food intake Effects 0.000 abstract description 19
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 206010053156 Musculoskeletal discomfort Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 230000035488 systolic blood pressure Effects 0.000 description 14
- 230000035487 diastolic blood pressure Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000006872 improvement Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 239000002689 soil Substances 0.000 description 8
- CVSVTCORWBXHQV-UHFFFAOYSA-N anhydrous creatine Natural products NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 229940116269 uric acid Drugs 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 239000003809 bile pigment Substances 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- 238000009535 clinical urine test Methods 0.000 description 4
- 239000006046 creatine Substances 0.000 description 4
- 229960003624 creatine Drugs 0.000 description 4
- -1 creatine lactam Chemical class 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000015001 muscle soreness Diseases 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- QHBZHVUGQROELI-UHFFFAOYSA-N Royal Jelly acid Natural products OCCCCCCCC=CC(O)=O QHBZHVUGQROELI-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- QHBZHVUGQROELI-SOFGYWHQSA-N (E)-10-hydroxydec-2-enoic acid Chemical compound OCCCCCCC\C=C\C(O)=O QHBZHVUGQROELI-SOFGYWHQSA-N 0.000 description 1
- KUPHXIFBKAORGY-UHFFFAOYSA-N 2-amino-3-iodo-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(N)=C1I KUPHXIFBKAORGY-UHFFFAOYSA-N 0.000 description 1
- VGMJVAHMQHPOGC-UHFFFAOYSA-N 3-amino-2-oxopropanoic acid Chemical compound NCC(=O)C(O)=O VGMJVAHMQHPOGC-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 241001482108 Alosa pseudoharengus Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229930003270 Vitamin B Chemical group 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical group CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Chemical group 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Jellies, Jams, And Syrups (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002061181A JP2003219816A (ja) | 2002-01-31 | 2002-01-31 | ローヤルゼリーを含有する食品および薬剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200415994A true TW200415994A (en) | 2004-09-01 |
| TWI335802B TWI335802B (enExample) | 2011-01-11 |
Family
ID=27751169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092104299A TW200415994A (en) | 2002-01-31 | 2003-02-27 | Food and medicine containing royal jelly |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2003219816A (enExample) |
| TW (1) | TW200415994A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI497334B (zh) * | 2013-03-07 | 2015-08-21 | Yen Ju Huang | 健康資料收集整合利用裝置及系統 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007137778A (ja) * | 2005-11-15 | 2007-06-07 | Pola Chem Ind Inc | 低密度リポタンパク受容体の発現促進剤及びそれを含有する食品 |
| JP5765879B2 (ja) * | 2008-08-01 | 2015-08-19 | 小林製薬株式会社 | 蜂の子、プロポリス、およびローヤルゼリーを含有する経口摂取用組成物 |
| KR101444232B1 (ko) | 2012-03-26 | 2014-09-30 | 대한민국 | 피부 노화 억제용 화장료 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0466062A (ja) * | 1990-07-06 | 1992-03-02 | Iwatani Internatl Corp | 凍結生ロイヤルゼリーの製造方法 |
| JPH0967252A (ja) * | 1995-09-05 | 1997-03-11 | Zenkoku Royal Jelly Kosei Torihiki Kiyougikai | ローヤルゼリーに含まれるトランス−１０−ヒドロキシ−デセン酸を有効成分とするアンジオテンシン転換酵素阻害剤及びインスリン様作用剤 |
| JP3047325B2 (ja) * | 1997-01-07 | 2000-05-29 | 謙二 徳永 | 品質劣化を抑制したローヤルゼリー錠剤の製造方法 |
| JP2989577B2 (ja) * | 1998-03-27 | 1999-12-13 | 株式会社セラリカ野田 | 健康飲料 |
| JPH11285360A (ja) * | 1998-04-03 | 1999-10-19 | Seiwa Yakuhin Kk | 機能性健康食品 |
| JP2000106830A (ja) * | 1998-10-02 | 2000-04-18 | Mitsuyori Inoue | 凍結レアフーズとその製造方法 |
| JP3061616B1 (ja) * | 1999-04-09 | 2000-07-10 | 株式会社セラリカ野田 | 低カロリ―調製ロ―ヤルゼリ― |
| JP3691685B2 (ja) * | 1999-06-22 | 2005-09-07 | 株式会社バイオックス | 血糖値上昇抑制剤 |
| JP2001157556A (ja) * | 1999-12-02 | 2001-06-12 | S F C:Kk | 健康食品およびその製造方法 |
| JP2001240549A (ja) * | 2000-03-01 | 2001-09-04 | Pola Chem Ind Inc | 免疫増強剤及びそれを含有してなる組成物 |
-
2002
- 2002-01-31 JP JP2002061181A patent/JP2003219816A/ja active Pending
-
2003
- 2003-02-27 TW TW092104299A patent/TW200415994A/zh not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI497334B (zh) * | 2013-03-07 | 2015-08-21 | Yen Ju Huang | 健康資料收集整合利用裝置及系統 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003219816A (ja) | 2003-08-05 |
| TWI335802B (enExample) | 2011-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8114837B2 (en) | Method for inhibiting postprandial rise in blood glucose by administering κ-casein | |
| CN102438642A (zh) | 包含绿茶提取物的组合物 | |
| JP2018502079A (ja) | ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び／又は刺激におけるその使用 | |
| TW201345538A (zh) | 牛樟芝用於治療疾病的方法 | |
| CN114832063B (zh) | 一种具有调节血糖、血脂和/或尿酸作用的组合物 | |
| Patel et al. | How much is too much? Exploring pseudohyperaldosteronism in glycyrrhizic acid toxicity from chronic licorice root consumption | |
| TW200415994A (en) | Food and medicine containing royal jelly | |
| US11596166B2 (en) | Compositions and methods for treating aging and/or improving human health | |
| KR101401884B1 (ko) | 광천수를 함유한 칼슘 보충용 조성물 | |
| WO1999047006A1 (fr) | Aliments, traitements medicaux et methodes visant a favoriser la croissance de lactobacillus bifidus, a prevenir les allergies et a reduire le taux de cholesterol chez l'homme | |
| CN102132873A (zh) | 一种具有补血和调节免疫功能的药品或者保健食品 | |
| Walsek et al. | Nutritional issues and HIV/AIDS: Assessment and treatment strategies | |
| CN101229330A (zh) | 一种竹笋提取物复合制剂及其中竹笋提取物的制备方法 | |
| CN108310123A (zh) | 一种用于预防和/或治疗高尿酸血症的药物组合物及其制备方法和用途 | |
| CN102578451A (zh) | 一种降血糖的保健食品组合物 | |
| JP2019509317A (ja) | 胃内容排出を増進させるインスリンの使用 | |
| CN100502914C (zh) | 一种治疗脑中风的中药组合物及其制备方法 | |
| WO2004075660A1 (ja) | ローヤルゼリーを含有する食品および薬剤 | |
| CN120346172B (zh) | 一种玛巴洛沙韦片的制备方法及其应用 | |
| CN115177658B (zh) | 一种用于降血糖的组合物 | |
| CN119097659B (zh) | 用于治疗颈动脉粥样硬化合并高脂血症的中药组合物、颗粒制剂及其制备方法 | |
| CN100502922C (zh) | 一种调节血压、调节血糖的胶囊 | |
| WO2021007933A1 (zh) | 五谷虫在用于治疗糖尿病中的应用 | |
| KR20050107772A (ko) | 로열 젤리를 함유하는 식품 및 약제 | |
| CN113476438B (zh) | 含二氢桑色素的降血糖组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MM4A | Annulment or lapse of patent due to non-payment of fees |